pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 13·1 min read
save

Takeda plans to cut 4,500 jobs, about 9% of workforce, under new CEO's restructuring plan

May 13, 2026·read at Endpoints ↗LayoffsNegative

Takeda announced it will eliminate roughly 9% of its global workforce, affecting about 4,500 positions, over the coming fiscal year.

The cuts are part of a restructuring effort that began under the current leadership and will be driven by the incoming chief executive.

The company said the reductions are intended to streamline operations and improve efficiency as it implements its long-term strategy.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Takeda to target 4,500 jobs as incoming CEO continues restructuring”

read at Endpoints ↗
81 words · retrieved May 13
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 12h agoFormer MIT professor David Sabatini awarded $6M in defamation caseEndpoints
  • 12h agoAntheia gets $80M conditional DOD loan to onshore to the USEndpoints
  • 14h ago#ESMO26 regular abstracts featuring Zai Lab, GSK, Merck and moreEndpoints
  • 16h agoGilead’s pill posts stronger colitis remission rates than EntyvioEndpoints
  • 16h agoEyePoint's Phase 3 failure; Lilly's China drug delivery dealEndpoints